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Glioblastoma (GBM) is one of the greatest challenges in oncology. The standard of
care therapy of this highly malignant brain tumor includes surgical resection
followed, one month after, by radiotherapy and chemotherapy with Temozolomide.
However, GBM still remains incurable mainly because of its anatomical location, high
intra - and inter-tumor heterogeneity and intrinsic characteristics that inevitably lead
to the formation of recurrences [1]. Considering that 80-90% of GBM recurrences are
localized in proximity of resection cavity borders we hypothesized to deliver an
injectable nanomedicine hydrogel directly in the tumor resection cavity after surgery
in order to obtain a sustained release of the drug. This could avoid the formation of
recurrences before starting the conventional treatment. The hydrogel that we have
developed and selected is formed of lipid nanocapsules (LNC) loaded with the
prodrug Lauroyl -gemcitabine (GemC12), which shows excellent radio-sensitizing
properties, could potentiate cancer immunotherapy and has a MGMT -independent
mechanism of action [2,3]. This nanomedicine hydrogel is injectable, adapted for
brain implantation and able to release the drug over one month in vitro [2]. In vivo,
the anti-tumor efficacy studies in a subcutaneous and ortothopic GBM rodent models
have shown, respectively, to decrease the tumor growth and increase the survival of
the mice after intratumoral injection of the hydrogel compared to the controls. Also,
to better mimic the clinical conditions, we have developed and validated a resection
model of the GBM orthotopic tumor and on -going anti -tumor efficacy studies after
administration of the treatment in the resection cavity are showing promising results.
Moreover, short -, mid- and long- term tolerability studies (1 week, 2 months and 6
months) indicated that this system is well tolerated in the brain. In conclusion, we
have demonstrated the fe asibility, safety and efficiency of the GemC12 -LNC
hydrogel for the local treatment of GBM. This system, which has a very simple
formulation and combines the properties and advantages of nanomedicines and
hydrogels, could be considered as a promising platform for the delivery of GemC12
for the local treatment of GBM.
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